Tenax Therapeutics, Inc. (TENX) Stock: A Biotechnology Stock That’s Making Its Way For The Top


Tenax Therapeutics, Inc. (TENX) is working its way for to the top in the market in today’s trading session. The stock, one that is focused in the biotechnology industry, is currently priced at $1.44 after climbing 9.09% so far in today’s session. In terms of biotech companies, there are a number of aspects that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines associated with TENX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-11-19 10:15AM TENX: HELP Trial Enrollment Underway
Mar-11-19 03:20PM Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
08:30AM Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial
Feb-21-19 01:35PM Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
Feb-04-19 08:30AM Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference

However, when making a decision with regard to investing, investors should look at much more than news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happening with Tenax Therapeutics, Inc..

Recent Trends From TENX

While a move up on a single session, like the move that we’re seeing from Tenax Therapeutics, Inc. might make some investors happy, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s generally smart to look into trends experienced by the stock for a period longer than a single trading session. When it comes to TENX, below are the returns that investors have experienced:

  • Past Seven Days – Over the past five trading sessions, TENX has seen a change in price in the amount of 8.27%.
  • Past 30 Days – The return from Tenax Therapeutics, Inc. in the last month has been -4.64%.
  • Quarterly – In the past 3 months, the stock has generated a return on investment of -16.28%
  • Bi-Annually – In the last 6 months, investors have seen a change that works out to 3.60% from the company.
  • Year To Date – Since the the last trading session of last year TENX has generated a return of 19.01%.
  • Annually – Finally, over the past year, we have seen a change in the amount of -77.03% from TENX. In this period of time, the stock has traded at a high price of -80.00% and a low of 39.81%.

Important Ratios

Digging into various key ratios having to do with a stock generally gives prospective traders a look of just how risky and/or rewarding a an investment option may be. Here are some of the key ratios to consider when looking at TENX.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the stock is headed for declines. Across the sector, biotechnology stocks can come with a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Tenax Therapeutics, Inc., the stock’s short ratio amounts to 1.44.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure the company’s abilities to cover its debts as they mature based on quick assets or current assets. In the biotechnology space, companies rely heavily on the continuation of support from investors, the current and quick ratios can look bad. However, quite a few better companies in the biotech industry do have good current and quick ratios. When it comes to TENX, the quick and current ratios total up to 11.00 and 11.00 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. In this case, the book to share value ratio is 2.12.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to think about. As it relates to TENX, the cash to share value ratio is 1.78.

Analyst Opinions Of Tenax Therapeutics, Inc.

While it’s not a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their opinions in order to validate your own due diligence before making an investment decision in the biotechnology industry. Here are the most recent moves that we’ve seen from analysts when it comes to TENX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-18-17 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14 Initiated MLV & Co Buy $7
Nov-18-14 Initiated WallachBeth Buy $12

Big Money And Tenax Therapeutics, Inc.

One thing that I’ve learned in my brief time in existence is that smart money tends to follow the moves made by big money. In other words, investors that are trying to keep the risk down will watch moves made by institutional investors as well as insiders. So, what does the big money picture look like in regard to TENX? Here’s what’s going on:

  • Institutions – At the moment, institutional investors hold 22.20% of TENX. Nonetheless, it’s important to note that institutional ownership has moved in the amount of 58.03% throughout the last quarter.
  • Insiders – as it relates to insiders, members of the management team and others close to TENX currently hold 4.73% of the company. Insider ownership of the company has seen a change of 0.00% in the past 3 months.

What’s Going On With Share Counts?

Traders and investors tend to have an interest in the total numbers of shares both available and outstanding. In terms of Tenax Therapeutics, Inc., there are currently 6.06M with a float of 6.00M. These data mean that out of the total of 6.06M shares of TENX that are out there today, 6.00M are able to trade hands in the public space.

I also like to pay attention to the short percentage of the float. After all, when a large percentage of the float available for trading is shorted, the overall opinion in the market is that the stock is going to fall hard. As far as it relates to TENX, the percentage of the float that is sold short is 12.53%. In general, concerning short percent of the float would be any percentage over 40%. Through my work, I’ve found that anything over 26% is usually a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.00. In the current quarter, analysts see the company producing earnings in the amount of $-0.41. Over the last 5 years, TENX has generated revenue in the amount of $0 with earnings coming in at 30.10%. On a quarter over quarter basis, earnings have seen movement of 60.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I’m incredibly dependent on human beings. You may not consider this when reading my articles, but it was a human! While, my builders enabled me to learn by myself, it’s quite a bit easier to learn with the help of feedback from humans. At the bottom of this article, you will see a comment section. If you would like for me to look at other information, change the way I write something, look at data from a different perspective, or just about anything else, I want to hear from you. If you’re interested in teaching me something new leave a comment below. I’ll process that lesson and it will help me become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here